Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Journal of Clinical Oncology

Volumn 33, Issue 10, 2015, Pages 1151-1156

  Klotz, Laurence ^a   O'Callaghan, Chris ^c   Ding, Keyue ^c   Toren, Paul ^e   Dearnaley, David ^f   Higano, Celestia S ^g   Horwitz, Eric ^h   Malone, Shawn ^d   Goldenberg, Larry ^e   Gospodarowicz, Mary ^b   Crook, Juanita M ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g FOX CHASE CANCER CENTER   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; HORMONE RESISTANCE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; TESTOSTERONE BLOOD LEVEL; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TIME FACTOR;

AGED; ANDROGEN ANTAGONISTS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TESTOSTERONE; TIME FACTORS;

EID: 84927564328     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.2973     Document Type: Article

References (15)

1. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate-1941. J Urol 168:9-12, 2002
2. Morote J, Planas J, Salvador C, et al: Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 103:332-335, 2009
3. Pickles T, Hamm J, Morris WJ, et al: Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: Does it happen and does it matter? BJU Int 110:E500-E507, 2012
4. Morote J, Orsola A, Planas J, et al: Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178:1290-1295, 2007
5. Perachino M, Cavalli V, Bravi F: Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? BJU Int 105:648-645, 2010
6. Bertaglia V, Tucci M, Fiori C, et al: Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 11:325-330, 2013
7. Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58:2546-2550, 1986
8. Abrahamsson PA: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 57:49-59, 2010
9. Crook JM, O'Callaghan CJ, Duncan G, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
10. Hochberg Y: A sharp Bonferroni procedure for multiple tests of significance. Biometrics 75:800-802, 1988
11. Tombal B, Berges R: Optimal control of testosterone: A clinical case based approach of modern androgen-deprivation therapy. Eur Urol 7:15-21, 2008 (suppl)
12. Mohler JL: Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 617:223-234, 2008
13. Hussain M, Tangen CM, Berry DL, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-1325, 2013
14. Kawata H, Ishikura N, Watanabe M, et al: Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70:745-754, 2010
15. Klotz L, Toren P: Androgen deprivation therapy in advanced prostate cancer: Is intermittent therapy the new standard of care? Curr Oncol 19: S13-S21, 2012 (suppl 3)